Clinical trials: Prostate Cancer Stage
Prostate Cancer
Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer
Vitamin D promotes the differentiation of prostate cancer cells, maintains the differentiated phenotype of prostate epithelial cells, and can induce prostate cancer cell death, raising the possibility that vitamin D deficiency…
- Trial name
- vit D & PCa (NCT00953225)
- Testing
- vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 83 people
- Sponsor
- VA Office of Research and Development
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited…
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma
- Trial name
- NCT05053152
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 245 sites in United States, Canada
- Volunteers
- 194 people
- Sponsor
- NRG Oncology
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04388852
- Testing
- Ipilimumab, Valemetostat
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started…
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06931340
- Testing
- Androgen Therapy, Apalutamide, Docetaxel
- Where
- 214 sites in United States
- Volunteers
- 1,260 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Castration-Sensitive Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
This phase II trial examines antiandrogen therapy interruptions in patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic) responding exceptionally well to androgen…
- Trial name
- A-DREAM (NCT05241860)
- Testing
- Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration
- Where
- 326 sites in United States
- Volunteers
- 79 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hormone Refractory Prostate Cancer
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC
This is a Phase II, open-label study in male patients with metastatic HRPC. Each cycle will be 21 days (3 weeks). Patients will receive the following drugs: Docetaxel 75 mg/m2 IV given over 1 hour on Day 1.
- Trial name
- NCT00313482
- Testing
- Sargramostim, Docetaxel, Prednisone
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Veeda Oncology
Stage I Prostate Cancer, Stage II Prostate Carcinoma
MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer
This phase II trial studies how well magnetic resonance (MR)-guided laser interstitial thermal therapy works in treating patients with prostate cancer.
- Trial name
- NCT01792024
- Testing
- Visualase Thermal Therapy, magnetic resonance imaging
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Chicago
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill prostate tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have…
- Trial name
- NCT00010127
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Prostate Cancer
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:
Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively.
- Trial name
- 5STAR-PC (NCT04245670)
- Testing
- Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer
The purpose of this research study is to find out the toxicities of doxercalciferol given in combination with docetaxel (Taxotere®), as well as to see how well this combination works in the treatment of prostate cancer.
- Trial name
- NCT00582582
- Testing
- Docetaxel plus doxercalciferol
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer
This is phase I, open label, multicentre, dose-escalation study where both doses of talazoparib and pidnarulex will be escalated to define the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for the combination.
- Trial name
- REPAIR (NCT05425862)
- Testing
- Pidnarulex, Talazoparib
- Where
- 5 sites in Australia
- Volunteers
- 4 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer
Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer
RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. It is not yet known whether surgery is more effective than internal radiation in treating prostate cancer.
- Trial name
- NCT00023686
- Testing
- surgery, radiation
- Where
- 36 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Solid Tumors, Non-small Cell Lung Cancer
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive…
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03473925
- Testing
- Navarixin, Pembrolizumab
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I\&T) in combination with Olaparib in participants with mCRPC.
- Trial name
- NCT06909825
- Testing
- FPI-2265, Olaparib
- Where
- 4 sites in Australia
- Volunteers
- 85 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Prostate Cancer
A Study of Imatinib and Docetaxel in Prostate Cancer
The purpose of this study is to determine the effectiveness of two drugs, docetaxel and Gleevec®(also called imatinib), in prostate cancer that no longer responds to hormone therapy.
- Trial name
- NCT00251225
- Testing
- Gleevec, Docetaxel
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Leonard Appleman
Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
- Trial name
- NCT06616597
- Testing
- Abiraterone acetate, Dexamethasone, Metronidazole
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Castration-resistant Prostate Cancer
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
- Trial name
- VECTRA-01 (NCT07611110)
- Testing
- Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone
- Where
- 151 sites in United States, Australia and 22 more
- Volunteers
- 670 people
- Sponsor
- AstraZeneca
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT07468903
- Testing
- Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.